Circulating Tumor DNA Predict Recurrence and Aid Treatment Decisions in Colon Cancer
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 500
- 试验地点
- 1
- 主要终点
- patients treated with chemotherapy based on clinical prognosis compared to Oncocare detection prognosis
研究概览
简要总结
The purpose of the study is to determine the relationship between change of gene copies and recurrence，and the overall survival at 5 years after chemotherapy based on clinical prognosis compared to Oncocare detection prognosis.
详细描述
Colorectal cancer is the third most common cancer worldwide. About two-thirds of the patients have a good therapeutic effect by combining surgical adjuvant treatment. But there are still 30-40% of patients may relapse. Efficient relapse early surveillance and accurate treatment decisions can avoid excessive medical treatment，and keep timely intervention to tumor recurrence as well. That's very important to extend the survival of patients. Currently, the efficient surveillance tools recommended by surveillance guidelines include clinical assessment, serum carcinoembryonic antigen testing, colonoscopy and CT.
Cell-free DNA(cfDNA)，the free form of DNA in the plasma，derived from the normal cells, the abnormal cells (such as tumor cells) or external (such as viral DNA). The plasma cell-free DNA derived from tumor cells is the circulating tumour DNA(ctDNA).
As most solid tumors, including CRC, release ctDNA into the blood,precision medical applications of ctDNA liquid biopsy in colorectal cancer to predict recurrence and aid treatment decisions has become a hot topic.
Recent research shows that substantially all of colorectal cancer patients have somatic genetic alterations, including both single-base mutation and larger somatic structural variations (SSVs). Mutations in these genes can be used as biomarkers to evaluate tumor burden, predict recurrence and supply information for treatment decisions through monitor and quantify ctDNA.
In this program，sequencing the tissue from colorectal cancer patients by capture technology TM and next generation sequencing(NGS),the specific somatic mutations，the so-called biomarkers, can be found.The analysis results of sequencing can help to the study of tumor molecular pathology and supply information for targetable drug.The continuous monitoring of biomarkers in the plasma can predict recurrence and supply information for treatment decisions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Triple (Participant, Care Provider, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •more than eighteen, diagnosed with colorectal cancer， not chemotherapy history, Inform consent signed.
排除标准
- •Psychosocial disorder, No inform consent signed.
研究组 & 干预措施
high genetic risk and high clinical risk
on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
干预措施: OncoCare (Biological)
low genetic risk but high clinical risk
on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method，randomized design，and chemotherapy for colorectal carcinoma
干预措施: OncoCare (Biological)
low genetic risk but high clinical risk
on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method，randomized design，and chemotherapy for colorectal carcinoma
干预措施: chemotherapy for colorectal carcinoma (Drug)
high genetic risk but low clinical risk
on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
干预措施: OncoCare (Biological)
high genetic risk but low clinical risk
on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
干预措施: chemotherapy for colorectal carcinoma (Drug)
low genetic risk and low clinical risk
on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
干预措施: OncoCare (Biological)
结局指标
主要结局
patients treated with chemotherapy based on clinical prognosis compared to Oncocare detection prognosis
时间窗: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 66 weeks
次要结局
- the rate of gene copies change from primary detection to recurrence(From date of randomization until the date of first documented progression, assessed up to 100 weeks)
- Overall survival at 5 years(From date of randomization until the date of death from any cause, assessed up to 60 months)